Want to see GB:CTEC full AI Analyst Report?
CTEC Stock Chart & Stats
230.00 p
1.06 p(0.47%)
At close: 4:00 PM EST
230.00 p
1.06 p(0.47%)
Day’s Range― - ―
52-Week Range193.00 p - 259.30 p
Previous CloseN/A
Volume85.46K
Average Volume (3M)6.27M
Market Cap
£4.16B
Enterprise Value6.06K
Total Cash (Recent Filing)£75.03M
Total Debt (Recent Filing)£1.52B
Price to Earnings (P/E)33.4
Beta1.10
Next Earnings
Aug 04, 2026EPS Estimate
0.06Next Dividend Ex-DateN/A
Dividend Yield2.11%
Share Statistics
EPS (TTM)0.09
Shares Outstanding1,954,852,000
10 Day Avg. Volume5,278,857
30 Day Avg. Volume6,266,139
Financial Highlights & Ratios
PEG Ratio-7.33
Price to Book (P/B)4.36
Price to Sales (P/S)2.66
P/FCF Ratio19.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£304.14Price Target Upside32.24% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)0.2
Revenue Forecast (FY)£2.56B
Bulls Say, Bears Say
Bulls Say
Consistent Organic Revenue GrowthConvaTec has delivered multi-year organic growth above mid-single digits and guides 5–7% for 2026 (ex-InnovaMatrix) with a 6–8% medium-term target. Durable demand for consumables, reimbursement-backed channels and repeat purchaser dynamics support predictable revenue that enables capacity investments and steady top-line expansion over the next several years.
Margin Expansion And ProfitabilityOperating margin improvement of several hundred basis points since 2021 reflects structural cost programs, pricing and mix shift to higher-margin categories. Management targets mid-20s operating margins, which if sustained would materially strengthen cash flow generation and support reinvestment and shareholder returns while insulating earnings from modest revenue swings.
Strong Cash Generation & Capital ReturnsRobust free cash flow and a demonstrated 100%+ conversion profile enable active capital allocation: buybacks, rising dividends and funding of growth capex. Reliable FCF provides a durable financial buffer to fund capacity expansion and product launches while allowing management to manage leverage and return capital without undermining operations.
Bears Say
InnovaMatrix Impairment & Reimbursement ShockA reimbursement-driven collapse and material impairment highlight exposure to sudden payer policy changes. This episode shows that acquired assets dependent on specific reimbursement rules can rapidly lose economic value, creating structural revenue volatility and requiring strategic re-evaluation of portfolio exposures to CMS and similar payors.
FDA Warning Letter On Complaints/CAPARegulatory process deficiencies represent a persistent operational risk: remediation can be lengthy, costly and may draw ongoing inspection attention. Weaknesses in quality systems increase the chance of enforced corrective actions, product distribution limits or reputational damage that can slow launches, raise compliance costs and constrain durable commercial growth.
Higher Leverage And Sub‑Ideal Cash ConversionLeverage has stepped up and free cash flow runs below reported net income, reducing flexibility. With growth capex rising and net debt having increased materially, higher leverage and less-than-ideal earnings-to-cash conversion heighten sensitivity to rate or margin pressure and limit optionality for large M&A or prolonged downturns.
ConvaTec News
CTEC FAQ
What was ConvaTec’s price range in the past 12 months?
ConvaTec lowest share price was 193.00 p and its highest was 259.30 p in the past 12 months.
What is ConvaTec’s market cap?
ConvaTec’s market cap is £4.16B.
When is ConvaTec’s upcoming earnings report date?
ConvaTec’s upcoming earnings report date is Aug 04, 2026 which is in 17 days.
How were ConvaTec’s earnings last quarter?
ConvaTec released its earnings results on Feb 24, 2026. The company reported 0.072 p earnings per share for the quarter, missing the consensus estimate of 0.074 p by -0.002 p.
Is ConvaTec overvalued?
According to Wall Street analysts ConvaTec’s price is currently Undervalued.
Does ConvaTec pay dividends?
ConvaTec pays a Semiannually dividend of 3.973 p which represents an annual dividend yield of 2.11%. See more information on ConvaTec dividends here
What is ConvaTec’s EPS estimate?
ConvaTec’s EPS estimate is 0.06.
How many shares outstanding does ConvaTec have?
ConvaTec has 1,954,852,000 shares outstanding.
What happened to ConvaTec’s price movement after its last earnings report?
ConvaTec reported an EPS of 0.072 p in its last earnings report, missing expectations of 0.074 p. Following the earnings report the stock price went up 10.397%.
Which hedge fund is a major shareholder of ConvaTec?
Currently, no hedge funds are holding shares in GB:CTEC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ConvaTec Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
£304.14 (32.24% Upside)
£304.14 (32.24% Upside)
Insider Transactions
Bought Shares
Worth £150.6K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
6.61%
12-Months-Change
Fundamentals
Return on Equity
10.53%
Trailing 12-Months
Asset Growth
0.16%
Trailing 12-Months
Company Description
ConvaTec
ConvaTec Group Plc operates as a global medical technology company, specializing in the creation, production, and worldwide distribution of a diverse array of healthcare products. Its offerings span critical areas, including advanced wound care, where it provides specialized dressings and skin care items for managing acute and chronic wounds that arise from conditions like diabetes, immobility, venous disease, traumatic injuries, burns, or surgical recovery. The company is also a key provider in ostomy care, delivering essential devices, accessories, and support services for individuals living with a stoma due to conditions such as colorectal cancer, inflammatory bowel disease, bladder cancer, and obesity. Beyond wound and ostomy solutions, ConvaTec's portfolio extends to continence and critical care. This includes intermittent urinary catheters and related products designed to assist individuals with urinary continence issues stemming from spinal cord injuries, multiple sclerosis, spina bifida, and other urological disorders. They also furnish equipment for intensive care units and hospital settings, alongside advanced systems for managing acute fecal incontinence and monitoring urine output and intra-abdominal pressure. Additionally, ConvaTec supplies various disposable medical devices, such as wound drainage systems, urine collection bags, airway management tools, gastroenterology tubes, and securement devices. The company manufactures disposable infusion sets for insulin pumps used in diabetes treatment, as well as for other continuous infusion therapies. These products reach pharmacies, hospitals, and both acute and post-acute healthcare providers directly, or through a network of distributors and wholesalers, catering to healthcare professionals, patients, and other manufacturers. Established in 1978, ConvaTec Group Plc is headquartered in Reading, United Kingdom.
CTEC Stock 12 Month Forecast
Average Price Target
304.14 p
▲(32.24% Upside)